Substance / Medication

Naphazoline hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Sinusitis

Rhinitis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Evaluation of Gingival Displacement with Aluminum Chloride and Naphazoline Hydrochloride: A Randomized Controlled Trial.

de Carvalho W F, Junior L C V, Junior H F B et al. · Eur J Prosthodont Restor Dent · 2021

PMID: 33026719RCT

Allergic contact dermatitis from dibucaine hydrochloride, chlorpheniramine maleate, and naphazoline hydrochloride in an over-the-counter topical antiseptic.

Yamadori Yoshika, Oiso Naoki, Hirao Ayaka et al. · Contact Dermatitis · 2009

PMID: 19659969Case Report

Understanding ocular comfort differences between 0.7% olopatadine and 0.3% pheniramine maleate/0.025% naphazoline hydrochloride eye drops.

Lievens Chris, Pucker Andrew D, McGwin Gerald et al. · Clin Exp Optom · 2023

PMID: 35815690Other

Stability Indicating UHPLC-PDA Assay for Simultaneous Determination of Antazoline Hydrochloride and Naphazoline Hydrochloride in Ophthalmic Formulations.

Ali Amir, Farooq Umar, Ahmed Mahmood et al. · Acta Chim Slov · 2017

PMID: 28621384Other

Flow injection chemiluminescence determination of naphazoline hydrochloride in pharmaceuticals.

Iranifam Mortaza, Sorouraddin Mohammad H · Luminescence · 2014

PMID: 23463582Other

A validated stability-indicating HPLC method for the simultaneous determination of pheniramine maleate and naphazoline hydrochloride in pharmaceutical formulations.

Huang Taomin, Chen Nianzu, Wang Donglei et al. · Chem Cent J · 2014

PMID: 24485011OtherFull text (PMC)

Determination of naphazoline hydrochloride in biological and pharmaceutical samples by a quantum dot-assisted chemiluminescence system using response-surface methodology.

Imani-Nabiyyi Amin, Sorouraddin Mohammad H · Luminescence · 2014

PMID: 24733642Other

In situ modified screen printed and carbon paste ion selective electrodes for potentiometric determination of naphazoline hydrochloride in its formulation.

Mohamed Gehad G, El-Dien F A Nour, Frag Eman Y Z et al. · J Pharm Anal · 2013

PMID: 29403841OtherFull text (PMC)

Report: Simultaneous determination of naphazoline hydrochloride, chlorpheniramine maleate and methylene blue in their ternary mixture.

Ali Nouruddin Wageih, Hegazy Maha Ahmad, Abdelkawy Mohamad et al. · Pak J Pharm Sci · 2013

PMID: 23625443Other

Treatment with olopatadine and naphazoline hydrochloride reduces allergic conjunctivitis in mice through alterations in inflammation, NGF and VEGF.

Quan Lin, He Hua · Mol Med Rep · 2016

PMID: 26936233Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Naphazoline hydrochloride (substance)
SNOMED CT: 57583000
UMLS CUI: C0282259

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.